Costas K. Yannakou
Melbourne, VIC, Australia
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 32 publications
LTB-TREAT: A validated international prognostic model for time to treatment in low tumour burden follicular lymphoma.
Journal: British journal of haematology
Published: May 28, 2026
Secondary graft failure after autologous stem cell transplantation for primary central nervous system lymphoma responds to ciclosporin and eltrombopag.
Journal: Leukemia & lymphoma
Published: March 19, 2026
An evaluation of elranatamab for the treatment of myeloma: current evidence for treating relapsed/refractory disease and future directions.
Journal: Expert opinion on biological therapy
Published: February 23, 2026
Personalized Immunotherapy for T Cell Lymphomas: From Immune Escape to Precision Therapeutics.
Journal: Journal of personalized medicine
Published: September 30, 2025
Perioperative ctDNA as a prognostic biomarker in endometrial cancer - the CODEC study.
Journal: Translational oncology
Published: August 13, 2025
Perioperative ctDNA as a prognostic biomarker in endometrial cancer - the CODEC study.
Journal: Translational oncology
Published: August 13, 2025
Glofitamab Combined With Pola-R-CHP or R-CHOP as First Therapy in Younger Patients With High-Risk Large B-Cell Lymphoma: Results From the COALITION Study.
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: June 18, 2025
Circulating Tumour DNA Is a Biomarker of Response in Angioimmunoblastic T-Cell Lymphoma.
Journal: International journal of molecular sciences
Published: June 07, 2025
An evaluation of odronextamab for the treatment of multiple subtypes of relapsed/refractory B-cell non-Hodgkin lymphoma.
Journal: Expert opinion on biological therapy
Published: March 19, 2025
Toxicities associated with lymphoma-targeting bispecific antibodies-a review.
Journal: Frontiers in medicine
Published: February 25, 2025
Efficacy and Safety of Denileukin Diftitox-Cxdl, an Improved Purity Formulation of Denileukin Diftitox, in Patients With Relapsed or Refractory Cutaneous T-Cell Lymphoma.
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: December 19, 2024
Last Updated: 09/26/2026